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Background: Osteosarcoma is the most common primary malignant bone tumor in children and young adults.
Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.
Findings: In this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for
GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples
from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.
Conclusions: GD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in
children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.
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Osteosarcoma is the most common primary malignancy
of the bone in children and young adults. Survival out-
comes for children with osteosarcoma have remained
stagnant for the past three decades. Novel therapeutic
approaches are needed to improve outcomes for these
patients. Studies have demonstrated that targeting the
ganglioside GD2 in patients with high risk neuroblast-
oma improves survival [1]. Our group recently reported
that GD2 is expressed in osteosarcoma, and the data
suggested GD2 expression may be increased in relapsed
specimens. However, the previous study lacked matched
samples to make definitive conclusions [2].
One challenge in molecularly targeted therapy is the
“moving target” of the changing proteome of cancer
cells. Whether they stem from further acquisition of mu-
tations, genetic instability, microenvironmental factors,
epigenetic changes, or immunoediting, changes in cell
surface protein expression of recurrent tumors may lead
to resistance against targeted therapies [3-6]. In this* Correspondence: rgorlick@montefiore.org
1Division of Pediatric Hematology/Oncology, Children’s Hospital at
Montefiore, Albert Einstein College of Medicine, 3415 Bainbridge Ave,
Rosenthal Pavilion, Room 300, Bronx, NY 10467, USA
5Department of Pediatrics and Molecular Pharmacology, Albert Einstein
College of Medicine, Bronx, NY, USA
Full list of author information is available at the end of the article
© 2015 Poon et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.study, we compared matched primary tumor samples to
recurrent tumors to elucidate the stability of GD2
expression.Materials and methods
Patient samples
An osteosarcoma tissue microarray (TMA) was con-
structed at Seattle Children’s Hospital, Seattle, WA with
prospective approval from the local Institutional Review
Board. The TMA was constructed to include tumor tis-
sue obtained at the time of initial diagnosis (from either
the primary or metastatic site), at the time of definitive
surgery, and at the time of disease recurrence (either
local or metastatic). In total 119 cores from 57 separate
specimens (of which 49 specimens were deemed useable
following the construction and staining process) repre-
senting 14 different patients were included in construction
of the TMA, as shown in Additional file 1: Figure S1. Each
core was included as a separate data point in the
analysis.
The TMAs were constructed using 2 mm cores obtained
from the original formalin-fixed paraffin-embedded tissue
block for each individual specimen. Each specimen was
sampled in at least duplicate. Four micron thick unstained
sections were then cut from the TMA block for subse-
quent immunohistochemical studies.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The tissue microarray slides were stained for GD2 ex-
pression using 100ug/ml of 14.G2a antibody as previ-
ously described [2]. 14.G2a antibody was a generous gift
from Dr. Karen Muszynski at the National Cancer Insti-
tute. Scoring was performed using a Nikon Inverted
Microscope ECLIPSE TE200 (Nikon Instruments Inc,
Tokyo, Japan) attached to a CCD (Diagnostic Instru-
ments, Sterling Heights, Michigan) by three scientists
with experience scoring tissue microarrays.
Tissue samples were scored as negative (−) if there
was no staining seen. A melanoma section known to ex-
press GD2 was used as a positive control and reference
for positive staining. Samples were scored as positive
(+++) if 67% to 100% of the section demonstrated the
same intensity and distribution of staining. Slides were
considered intermediate (++) if 34% to 66% of cells
stained positive, and were scored as sporadic (+) when
only 1% to 33% of cells stained positive. Tissue sections
were graded by 3 independent observers blinded to the
patient information. Clinical data for correlative analyses
were obtained from Seattle Children’s Hospital only after
all grading had been completed.
Statistical analysis
Immunohistochemical assays for GD2 were assessed by
three independent observers, and the level of variability
between individuals was assessed using a two-factor
ANOVA without replacement. When there was disagree-
ment between the 3 observers, the median value was se-
lected as the final tissue grading. Duplicate sample cores
were assessed for agreement, and in cases of discord-
ance, the higher value was selected as the final grading.
A Mann–Whitney U-test was used to determine differ-
ences in GD2 expression levels in the primary biopsy
specimens compared with the recurrent disease speci-




Forty-nine samples from 14 osteosarcoma patients re-
mained for examination, taken at primary biopsy (10%
of samples), metastases at diagnosis (4%), primary dis-
ease treated with neoadjuvant therapy at the time ofTable 1 GD2 expression in osteosarcoma samples
assessed by immunohistochemistry
Unique cores - + ++ +++
Primary 5 0 1 4 0
Metastases at Diagnosis 2 0 1 0 1
Treated resection 10 1 3 3 3
Recurrent 32 1 7 12 12definitive surgery (20%) and at disease recurrence (65%)
(Table 1). Five patients with samples from initial biopsies
with matched recurrent samples were available for
evaluation in the current study; two of recurrent sample
cores were from local recurrences (16%), and the
remaining sample cores were from distant lung metasta-
ses (84%). One patient, with 2 samples from different re-
gions of the tumor in the initial biopsy, did not have a
biopsy from disease recurrence available for comparison.
Mean patient age was 14.2 years (range 7–19) and 71%
of patients were male. Tumor histology was classified as
osteoblastic (64%) or chondroblastic (36%) and the most
common primary tumor sites were the femur (64%),
tibia (21%), humerus (7%) and pelvis (7%). All patients
were treated with high-dose methotrexate, doxorubicin
and cisplatin, with one patient receiving additional ifos-
famide, and two patients receiving additional ifosfamide
and etoposide. Additional patient characteristics can be
seen in Additional file 2: Table S1.
GD2 expression
The level of variability between three independent ob-
servers was assessed to be non-significant using a two-
factor ANOVA without replacement (p = 0.24), and the
intraclass correlation coefficient was found to be 0.72,
suggesting a fair to good level of agreement. The tissue
microarray of 49 samples stained with the monoclonal
antibody 14G2A demonstrated GD2 expression in 95%
of samples. Ninety-seven percent of all recurrent disease
specimens analyzed expressed GD2, however, the level
of expression was not significantly different (p = 0.15)
between initial biopsy samples compared with treated
resection samples (Figure 1). Recurrent disease speci-
mens demonstrated varied expression of GD2 amongst
core biopsies from the same patient. Level of GD2 ex-
pression was not significantly different between initial
primary biopsy specimens and matched recurrent
disease specimens, whether the recurrence was local
(Figure 2A) or distant (Figure 2B-D).
Discussion
Over the past few decades there has been limited im-
provement in outcomes for patients with osteosarcoma.
The identification of specific molecular targets has the
potential to improve patient outcomes with the use of
novel treatment strategies. The current data demonstrate
that the surface protein ganglioside GD2 is stably
expressed in osteosarcoma [2]. This provides a rationale
for assessing the efficacy of anti-GD2 antibody therapy
in osteosarcoma patients with recurrent disease.
In contrast to the prior report, samples did not show
increased levels of GD2 expression upon recurrence.
Matched cores from recurrent samples showed varying
expression of GD2, with no significant change of
Figure 1 Expression of GD-2 in osteosarcoma cores. Cores taken
from the primary biopsy, metastases at diagnosis, treated
resection and upon recurrence were stained with a GD-2 specific
antibody and examined via immunohistochemistry. Three
independent observers scored the samples on a scale from –
to +++. No significant difference in expression was seen be-
tween primary biopsy/treated resection samples versus recurrent
samples (p = 0.15).
Figure 2 Variation in GD-2 expression between primary and recurren
data point represents one unique core, taken either from the primary biop
patients. The recurrent samples shown in panel A were taken from local re
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The variability in expression in the cores taken at recur-
rence may be due to the intratumoral heterogeneity, or
variability in the percentage of tumor versus stroma in-
cluded in the cores, as the location of the core relative
to the tumor architecture may have been reflected in
variation in the local tumor microenvironment. Future
studies could utilize multicolor IHC in order to identify
possible intratumoral factors that influence GD2 expres-
sion. It is possible that GD2 expressing cells represent a
subset of osteosarcoma cells or areas of highly prolifera-
tive cells [7,8]. In breast cancer, a number of groups have
suggested that GD2 may be a marker of cancer stem
cells, making them an especially attractive therapeutic tar-
get [9,10]. In such cases, examining markers for prolifera-
tion, such as Ki-67, or cancer stem cell markers, such as
CD44, may elucidate potential intratumoral effects.
As therapies targeting GD2, such as the therapeutic
antibody CH14.18, begin entering clinical testing in pa-
tients with osteosarcoma, monitoring potential loss of
GD2 expression on osteosarcoma cells may aid in pre-
dicting possible development of treatment resistance.
Interestingly, in patients with neuroblastoma, GD2 ex-
pression was maintained even after treatment with the
anti-GD2 antibody 3 F8 [11].
The current study is limited by overall sample num-
bers, and it is possible that our analyses lacked the
power to delineate differences in GD2 expression.
However, coupled with our previous studies, it is clear
that GD2 is expressed in both primary and recurrent
osteosarcoma [2].t tumor cores from the 4 patients with matched samples. Each
sy or from a single recurrent sample. Panels A-D indicate unique
currence, while panels B-D show patients with distant lung metastases.
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primary and recurrent osteosarcoma samples, it is un-
likely that GD2 expression is a prognostic biomarker,
but the relatively limited number of samples examined
makes this difficult to assess. However, the expression of
GD2 on nearly all primary and recurrent osteosarcoma
specimens suggests it is an attractive target for antibody-
mediated therapy. Clinical trials are needed to assess the
efficacy of anti-GD2 antibody therapy in patients with
osteosarcoma.
Additional files
Additional file 1: Figure S1. Workflow of the tumor biopsy sectioning,
scoring, and analysis.
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